RA Capital Management Discloses 14.6% Stake in Bambusa Therapeutics
The filing names Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. as joint filers and gives Oct. 30 as the date of the event that required it.
RA Capital Management, L.P. reported beneficial ownership of 7,429,758 shares of Bambusa Therapeutics, Inc., or 14.6% of its common stock, according to a Schedule 13D filed Nov. 6 with the US Securities and Exchange Commission.
The filing says the holdings include 5,933,787 shares held directly by RA Capital Healthcare Fund, L.P. and 1,495,971 shares held directly by RA Capital Nexus Fund III, L.P. RA Capital serves as investment adviser for both funds, according to the filing. The percentage is based on 50,942,430 shares of common stock outstanding, as reported in Bambusa's final prospectus.
The reporting persons hold the shares "for investment purposes and not with an intent, purpose or effect of changing control of the Issuer," the filing says. It says they have no present plans or proposals of the kind the form asks about, though they may change their purpose at any time.
Dr. Derek DiRocco, a Partner of RA Capital, serves as a director of Bambusa, according to the filing.
The filing says both funds signed lock-up agreements with the underwriters of Bambusa's initial public offering that bar them, with limited exceptions, from disposing of or hedging the company's securities for 180 days without the consent of BofA Securities, Inc. and Evercore Group L.L.C.